Melissa E Munroe1, Rufei Lu2, Yan D Zhao3, Dustin A Fife1, Julie M Robertson1, Joel M Guthridge1, Timothy B Niewold4, George C Tsokos5, Michael P Keith6, John B Harley7, Judith A James2. 1. Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. 2. Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA Department of Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. 3. Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. 4. Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 6. Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA. 7. Cincinnati Children's Hospital Medical Center and US Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA.
Abstract
OBJECTIVES: The relationship of immune dysregulation and autoantibody production that may contribute to systemic lupus erythematosus (SLE) pathogenesis is unknown. This study evaluates the individual and combined contributions of autoantibodies, type I interferon (IFN-α) activity, and IFN-associated soluble mediators to disease development leading to SLE. METHODS: Serial serum specimens from 55 individuals collected prior to SLE classification (average timespan=4.3 years) and unaffected healthy controls matched by age (±5 years), gender, race and time of sample procurement were obtained from the Department of Defense Serum Repository. Levels of serum IFN-α activity, IFN-associated mediators and autoantibodies were evaluated and temporal relationships assessed by growth curve modelling, path analysis, analysis of covariance and random forest models. RESULTS: In cases, but not matched controls, autoantibody specificities and IFN-associated mediators accumulated over a period of years, plateauing near the time of disease classification (p<0.001). Autoantibody positivity coincided with or followed type II IFN dysregulation, preceding IFN-α activity in growth curve models, with elevated IFN-α activity and B-lymphocyte stimulator levels occurring shortly before SLE classification (p≤0.005). Cases were distinguished by multivariate random forest models incorporating IFN-γ, macrophage chemoattractant protein (MCP)-3, anti-chromatin and anti-spliceosome antibodies (accuracy 93% >4 years pre-classification; 97% within 2 years of SLE classification). CONCLUSIONS: Years before SLE classification, enhancement of the type II IFN pathway allows for accumulation of autoantibodies and subsequent elevations in IFN-α activity immediately preceding SLE classification. Perturbations in select immunological processes may help identify at-risk individuals for further clinical evaluation or participation in prospective intervention trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: The relationship of immune dysregulation and autoantibody production that may contribute to systemic lupus erythematosus (SLE) pathogenesis is unknown. This study evaluates the individual and combined contributions of autoantibodies, type I interferon (IFN-α) activity, and IFN-associated soluble mediators to disease development leading to SLE. METHODS: Serial serum specimens from 55 individuals collected prior to SLE classification (average timespan=4.3 years) and unaffected healthy controls matched by age (±5 years), gender, race and time of sample procurement were obtained from the Department of Defense Serum Repository. Levels of serum IFN-α activity, IFN-associated mediators and autoantibodies were evaluated and temporal relationships assessed by growth curve modelling, path analysis, analysis of covariance and random forest models. RESULTS: In cases, but not matched controls, autoantibody specificities and IFN-associated mediators accumulated over a period of years, plateauing near the time of disease classification (p<0.001). Autoantibody positivity coincided with or followed type II IFN dysregulation, preceding IFN-α activity in growth curve models, with elevated IFN-α activity and B-lymphocyte stimulator levels occurring shortly before SLE classification (p≤0.005). Cases were distinguished by multivariate random forest models incorporating IFN-γ, macrophage chemoattractant protein (MCP)-3, anti-chromatin and anti-spliceosome antibodies (accuracy 93% >4 years pre-classification; 97% within 2 years of SLE classification). CONCLUSIONS: Years before SLE classification, enhancement of the type II IFN pathway allows for accumulation of autoantibodies and subsequent elevations in IFN-α activity immediately preceding SLE classification. Perturbations in select immunological processes may help identify at-risk individuals for further clinical evaluation or participation in prospective intervention trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold Journal: Arthritis Rheum Date: 2011-04
Authors: Minoru Satoh; Edward K L Chan; Lindsey A Ho; Kathryn M Rose; Christine G Parks; Richard D Cohn; Todd A Jusko; Nigel J Walker; Dori R Germolec; Irene Z Whitt; Patrick W Crockett; Brad A Pauley; Jason Y F Chan; Steven J Ross; Linda S Birnbaum; Darryl C Zeldin; Frederick W Miller Journal: Arthritis Rheum Date: 2012-07
Authors: Pooneh S Akhavan; Jiandong Su; Wendy Lou; Dafna D Gladman; Murray B Urowitz; Paul R Fortin Journal: J Rheumatol Date: 2013-04-15 Impact factor: 4.666
Authors: Latisha D Heinlen; Micah T McClain; Joan Merrill; Yasmin W Akbarali; Colin C Edgerton; John B Harley; Judith A James Journal: Arthritis Rheum Date: 2007-07
Authors: J A James; X R Kim-Howard; B F Bruner; M K Jonsson; M T McClain; M R Arbuckle; C Walker; G J Dennis; J T Merrill; J B Harley Journal: Lupus Date: 2007 Impact factor: 2.911
Authors: Murray B Urowitz; Dafna D Gladman; Dominique Ibañez; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Anne E Clarke; Sasha Bernatsky; Paul R Fortin; John G Hanly; David Isenberg; Anisur Rahman; Daniel J Wallace; Ellen Ginzler; Michelle Petri; Ian N Bruce; Joan T Merrill; Ola Nived; Gunnar Sturfelt; Mary Anne Dooley; Graciela S Alarcón; Barri Fessler; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad Zoma; Munther Khamashta; Susan Manzi; Ronald van Vollenhoven; Manuel Ramos-Casals; Cynthia Aranow; Thomas Stoll Journal: J Rheumatol Date: 2014-04-01 Impact factor: 4.666
Authors: Vaishali R Moulton; Abel Suarez-Fueyo; Esra Meidan; Hao Li; Masayuki Mizui; George C Tsokos Journal: Trends Mol Med Date: 2017-06-13 Impact factor: 11.951